Author:

Keywords:

atherosclerotic cardiovascular diseases, pre-clinical disease, established disease, cost-of-illness analysis, belgium, coronary-heart-disease, hartslag limburg, risk-factors, population, prevalence, stroke, atherothrombosis, intervention, hypertension, prevention, Science & Technology, Life Sciences & Biomedicine, Cardiac & Cardiovascular Systems, Pharmacology & Pharmacy, Cardiovascular System & Cardiology, Atherosclerotic cardiovascular diseases, Pre-clinical disease, Established disease, Cost-of-illness analysis, Belgium, CORONARY-HEART-DISEASE, HARTSLAG LIMBURG, RISK-FACTORS, POPULATION, PREVALENCE, STROKE, ATHEROTHROMBOSIS, INTERVENTION, HYPERTENSION, PREVENTION, Atherosclerosis, Cerebrovascular Disorders, Coronary Artery Disease, Cost of Illness, Cost-Benefit Analysis, Female, Financing, Personal, Health Care Costs, Humans, Insurance, Health, Reimbursement, Male, Peripheral Vascular Diseases, Prevalence, Preventive Health Services, Sensitivity and Specificity, 1115 Pharmacology and Pharmaceutical Sciences, Cardiovascular System & Hematology, 3201 Cardiovascular medicine and haematology, 3214 Pharmacology and pharmaceutical sciences

Abstract:

This study aims to quantify costs of atherosclerotic cardiovascular diseases in Belgium in 2004.